Biotest Aktiengesellschaft (0N6Z.L)
| Previous close | 42.50 |
| Open | 43.30 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 42.50 - 44.01 |
| 52-week range | 42.50 - 44.01 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 1.531B |
| Beta (5Y monthly) | 0.49 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.72 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- EQS Group
Biotest AG: Biotest AG opens eighth plasma collection centre in Czech Republic
DGAP-News: Biotest AG / Key word(s): Miscellaneous12.01.2022 / 07:00 The issuer is solely responsible for the content of this announcement.PRESS RELEASEBiotest AG opens eighth plasma collection centre in Czech Republic 28 plasma collection centres in Europe to ensure long-term plasma supplyDreieich, 12 January 2022. Biotest has received the operating license for its eighth plasma collection centre in Czech Republic from the country's national public health authority SUKL. The centre is located i
- EQS Group
Biotest AG: Grifols, S.A. will hold more than 95,5498 % of the voting rights upon settlement of the takeover offer
Biotest AG / Key word(s): OfferBiotest AG: Grifols, S.A. will hold more than 95,5498 % of the voting rights upon settlement of the takeover offer07-Jan-2022 / 13:51 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Ad-hoc RELEASEAnnouncement according to Article 17 European Market Abuse Regulation (MAR)Grifols, S.A. will hold m
- EQS Group
Biotest AG: Biotest treats first CMV-positive pregnant woman in Phase III clinical trial to prevent transmission of CMV infection to the unborn child
DGAP-News: Biotest AG / Key word(s): Research Update14.12.2021 / 07:00 The issuer is solely responsible for the content of this announcement.PRESS RELEASEBiotest treats first CMV-positive pregnant woman in Phase III clinical trial to prevent transmission of CMV infection to the unborn child- Cytomegalovirus (CMV) infection of the foetus is one of the most common congenital infections and may cause severe developmental retardation and hearing loss in new-borns - High unmet medical need due to lar
